Please assess the completion status of the following clinical trial:

Trial Title: Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Are male or female aged 18-75 years at the time of signing the informed consent form.~* Have been diagnosed as mCRC verified histologically~* Having one or more bi-dimensionally measurable lesions as defined by Response Evaluation Criteria In Solid Tumors (RECIST) criteria,~* Was not felt to be amenable to curative resection,~* With an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1~* Life expectancy of longer than 3 months ( clinical assessment)~* Adequate organ and marrow function as defined below:~  * Absolute neutrophil count (ANC) greater than/equal to 1,500/mm3;~ * Platelets greater than/equal to 100,000/ mm3;~ * Hemoglobin greater than/equal to 9 gm/dl (may be transfused to maintain or exceed this level);~ * Total bilirubin less than/equal to 1.5 within institutional upper limit of normal (IULN);~ * Aspartate aminotransferase (AST or SGOT)/alanine aminotransferase (ALT or SGPT) less than/equal to 2.5 times IULN, or less than/equal to 5 times IULN if known liver metastases;~* May have received adjuvant therapy for primary colorectal cancer provided that at least 6 months have elapsed from the time the adjuvant therapy was concluded and recurrent disease was documented~* Patients with history of hypertension must be well-controlled (blood pressure less than/equal to 150/100), on a stable regimen of anti-hypertensive therapy.~Exclusion Criteria:~* Prior targeted therapy for mCRC~* Radiotherapy or surgery for mCRC less than 4 weeks before random assignment.~* Undergone major surgical procedures or open biopsy within 28 days before the initiation of study treatment~* Experienced significant traumatic injury, within 28 days before study entry~* Currently using or had recently used therapeutic anticoagulants, thrombolytic therapy, chronic, daily treatment with aspirin (higher than 325 mg/daily). (Patients may have prophylactic use of low molecular weight heparin, however therapeutic use of heparin or low molecular weight heparin is not acceptable)~* Proteinuria exceeding 500mg/24 h~* History or presence of central nervous system metastases~* Female patients who are pregnant or lactating~* Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab, irinotecan, 5-FU, or leucovorin~* Serious non-healing wound, ulcer, or active bone fracture~* Myocardial infarction within 6 months before of study enrollment;~* History of stroke within 6 months before of study enrollment;~* Clinically significant peripheral vascular disease;~* Uncontrolled diabetes; Serious active or uncontrolled infection~* Inability to comply with study and/or follow-up procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab) (Type: EXPERIMENTAL): Bevacizumab+FOLFIRI-3 (irinotecan, leucovorin, and 5-FU). Bevacizumab (AryoGen) 5 mg/kg will be administered every 2 weeks.
- Bevacizumab + FOLFIRI-3 (Roche Bevacizumab) (Type: ACTIVE_COMPARATOR): Bevacizumab+FOLFIRI-3 (irinotecan, leucovorin, and 5-FU). Bevacizumab (Avastin®) 5 mg/kg will be administered every 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete